US biopharmaceutical company iVeena has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its IVMED-85 eye drop for the treatment of paediatric myopia.
IVMED-85 is a preservative-free non-atropine prescription eye drop. Used daily, it’s designed to strengthen scleral and corneal collagen crosslinks through lysyl oxidase (LOX)* activation, potentially leading to improved refraction and a decrease in the rate of axial elongation.
“Today’s announcement is an important milestone for iVeena in our journey to offer patients a novel therapeutic option,” said president and founder, Dr Bala Ambati. “We look forward to initiating our multinational phase 2 study in the coming months.”






